In an effort to curb government spending and lower healthcare costs for millions of people in the United States, the Inflation Reduction Act (IRA) of 2022 introduced new government-mandated pricing concessions to drug discount programs. Adding further complexity to these already intricate programs, the new discount programs increase the risk of duplicate or even triplicate discounts, causing revenue leakage and financial uncertainty for manufacturers without effective discount management programs in place.
A thorough breakdown of the challenges and considerations manufacturers must understand is available in our whitepaper: “Operational complexity and evolving challenges: What drug manufacturers need to know now about drug discount programs, the Inflation Reduction Act and 340B.”
- The IRA introduced new pricing concessions that will add operational complexity to drug discount programs.
- Manufacturers without effective discount management programs will face higher revenue leakage and greater financial uncertainty.
- Drug manufacturers must take urgent action to understand the new drug discount provisions and ensure their management programs are modernized and effective.